ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,433.76
0.63%
Dow Jones
39,512.84
0.32%
Gold vs US Dollar
2,360.48
0.00%
Brent Oil
82.585
0.00%
Bitcoin
61,472.04
1.11%
Pepperstone
Advertisement
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Neurocrine Biosciences Inc (NBIX)

  7. Neurocrine Biosciences Inc (NBIX) News

Neurocrine Biosciences (NBIX)

Neurocrine Biosciences Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:NBIX
DateTimeSourceHeadlineSymbolCompany
09/05/202414:45PR Newswire (US)Neurocrine Biosciences Presents CAHtalyst™ Adult Study Baseline Characteristics and Data on Impact of Supraphysiologic Glucocorticoid Therapy at AACE 2024NASDAQ:NBIXNeurocrine Biosciences Inc
09/05/202413:30PR Newswire (US)Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1076986 in Healthy AdultsNASDAQ:NBIXNeurocrine Biosciences Inc
08/05/202421:26Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
08/05/202413:30PR Newswire (US)Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy AdultsNASDAQ:NBIXNeurocrine Biosciences Inc
07/05/202421:15PR Newswire (US)Neurocrine Biosciences to Present at the BofA Securities 2024 Health Care ConferenceNASDAQ:NBIXNeurocrine Biosciences Inc
07/05/202413:30PR Newswire (US)Neurocrine Biosciences to Present Phase 3 Baseline Characteristics Data from the CAHtalyst™ Program of Crinecerfont in CAH, and Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH Studies at ECE 2024NASDAQ:NBIXNeurocrine Biosciences Inc
06/05/202413:30PR Newswire (US)Neurocrine Biosciences Supports Tardive Dyskinesia Awareness Week by Advocating for Routine Screening and MonitoringNASDAQ:NBIXNeurocrine Biosciences Inc
03/05/202418:15PR Newswire (US)Neurocrine Biosciences Presented CAHtalyst™ Pediatric Study Baseline Characteristics and CAHtalog™ Registry Data at PES 2024NASDAQ:NBIXNeurocrine Biosciences Inc
01/05/202412:00PR Newswire (US)Neurocrine Biosciences Reports First Quarter 2024 Financial ResultsNASDAQ:NBIXNeurocrine Biosciences Inc
30/04/202422:12PR Newswire (US)Neurocrine Biosciences Announces U.S. FDA Approval of INGREZZA® SPRINKLE (valbenazine) CapsulesNASDAQ:NBIXNeurocrine Biosciences Inc
24/04/202413:30PR Newswire (US)Neurocrine Biosciences Launches WHAT THE C@H?! Educational Initiative to Support Congenital Adrenal Hyperplasia CommunityNASDAQ:NBIXNeurocrine Biosciences Inc
23/04/202412:00PR Newswire (US)Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive DisorderNASDAQ:NBIXNeurocrine Biosciences Inc
16/04/202421:01GlobeNewswire Inc.Sentia Medical Sciences and Neurocrine Biosciences Extend Research Collaboration to Discover Novel CRF PeptidesNASDAQ:NBIXNeurocrine Biosciences Inc
10/04/202421:01PR Newswire (US)Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2024 Financial ResultsNASDAQ:NBIXNeurocrine Biosciences Inc
03/04/202413:30PR Newswire (US)Neurocrine Biosciences Announces First-Patient Dosed in Phase 2 Clinical Study Evaluating NBI-1070770 in Adults with Major Depressive DisorderNASDAQ:NBIXNeurocrine Biosciences Inc
28/03/202412:30PR Newswire (US)Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1065890, a Second-Generation VMAT2 Inhibitor, in Healthy AdultsNASDAQ:NBIXNeurocrine Biosciences Inc
11/03/202420:01PR Newswire (US)Neurocrine Biosciences to Participate at Virtual Investor Conferences in MarchNASDAQ:NBIXNeurocrine Biosciences Inc
08/03/202421:22Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
08/03/202421:22Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
01/03/202400:02Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
29/02/202423:55Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
29/02/202423:50Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
27/02/202421:29Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
27/02/202421:01PR Newswire (US)Neurocrine Biosciences to Participate at Investor Conferences in MarchNASDAQ:NBIXNeurocrine Biosciences Inc
22/02/202422:11Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
20/02/202421:33Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
15/02/202422:51Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
15/02/202422:48Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
15/02/202422:45Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
15/02/202422:43Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
 Showing the most relevant articles for your search:NASDAQ:NBIX

Your Recent History

LSE
PET
Petrel Resources
LSE
SYME
Supply@me Capital
LSE
TERN
Tern
LSE
GOLD
LSE
GFM
Griffin Mining
LSE
CNR
Condor Gold
LSE
ITV
Itv
LSE
VAST
Vast Resources
LSE
ALBA
Alba Mineral Resources
LSE
BIRD
Blackbird
LSE
BBSN
Brave Bison
LSE
SRSP
Sirius Petroleum
LSE
LLOY
Lloyds Banking
LSE
THUS
Thus
LSE
SCE
Surface Transforms
LSE
LGEN
Legal & General
Delayed Upgrade Clock
    ADVFN Logo

    United Kingdom
    Company
    Business
    Popular
    Get The App

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved